Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05223673
Title Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Institut de Recherches Internationales Servier

colorectal adenocarcinoma


Trifluridine-tipiracil hydrochloride

Futuximab + Modotuximab

Age Groups: adult | senior
Covered Countries USA | BEL

Additional content available in CKB BOOST